Compare ConocoPhillips (COP) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? ConocoPhillips trades at $133.28 (market cap $161.21B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: ConocoPhillips is far larger — about 2.7× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| COP | TAK | |
|---|---|---|
Market Cap | $161.21B | $58.74B |
Volume | 6,058,403 | 3,110,994 |
Sector | Energy | Health |
52-Week High | $141.22 | $19.05 |
52-Week Low | $85.66 | $13.23 |
Typical Hold Time | 79 Days | 0 Days |
Enterprise Value | $176.81B | $86.65B |
Dividend Yield | 2.5% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $129.84, up 0.38% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a net income margin of 14.65% and a P/E of 17.17, while recent earnings beat expectations in Q1 and Q2 2026. A 20-year LNG supply deal with Venture Global, announced October 1, 2026, highlights strategic growth initiatives.
The outlook is positive, supported by a 75% analyst buy rating and a consensus price target of $154.75, implying 19% upside. Risks include geopolitical exposure in the Middle East and oil price volatility, but robust cash flow and shareholder returns provide stability for investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
